2026

CASE STUDY

Long-lasting fundraising support

Trusted by:

... and many others

CUSTOMER'S Profile

BiPER‘s name summarizes the unique approach of the lead candidate targeting BiP and leading to cancer cell death through unresolved ER Stress induction

They are developing a first-in-class pipeline of small molecules pushing cancer cells to burn out to treat cancers

Founded 2021

Private

Strasbourg, France

Series A (raising)

biper-tx.com

CHALLENGES

Ensure timely investment
Clean and clear Investor deck
Accessible MOA explanation
Comprehensive Website as 24/7 tool

THE GOAL

The ultimate goal was to streamline their fundraising efforts.

Update the pitch deck to build credibility, strengthen scientific communication and online presence, to provide clear value to current and potential investors.

- polished pitch deck including infographics;

- 2-min video;

- revamped website.

THE DELIVERABLES

Investor-facing video creation & Pitch deck adaptation

Biper progressed into the next stage of development

CLICK AT ANY STAGE TO SEE THE DETAILS

Corporate website upgrade

Biper completed the first close of its Series A

Upgrade of investor-facing video

2D 3D

Investor-facing video

2022

By using a combination of 2D and 3D we showed selective ligands of BiP that lead to cancer cell death through strong ER Stress induction. BPR001 triggers cell death selectively in Cancer cells through apoptosis and autophagy.

By using simple but instructive infographic we demonstrated the results that the drug showed during preclinical development.

back to the map

Pitch deck refinement

2022

The pitch deck was redesigned to clearly structure complex scientific and clinical data into a concise, investor-ready narrative.

The redesigned deck supports fundraising and partner discussions by translating detailed research results into a clear and compelling visual story.

back to the map

Video Update

2025

To enhance scientific depth, key 2D elements were replaced with 3D visuals, allowing complex ER stress–related processes to be presented in a more precise and engaging way for investors and partners.

back to the map

Video Update

2025

back to the map

Website Update

2025

back to the map

Website Update

2025

back to the map

Mehdi Chelbi

CEO & Co-Founder BIPER Therapeutics

CEO's feedback

Thanks to the newly developed comms assets, BiPER Therapeutics received the Boston Biotech Summit's Vice Champion Award and was nominated for the Best Startup category by The Galien Foundation.

"The newly developed comms assets contributed to BiPER Therapeutics fundraising rounds and enables BiPER Tx making the difference in world-classs high level awards Boston Biotech Summit Galien Fondation Price and World Health expo Start-up pitch competition"

Thank you for your patience and the great job

I decided to try working with Nanobot and was not disappointed. I was impressed by their systematic approach and the results I received, and I look forward to continuing our collaboration with this company

back to the map